What Kazmira does

Kazmira is a vertically integrated prescription cannabinoid company that pairs a LegitScript-certified 503A compounding pharmacy (Kazmira Pharmacy) with a direct-to-consumer telehealth platform (Cope Now) to deliver THC-free, prescription-only CBD at clinically effective doses. Founded in 2017 and headquartered in Watkins, Colorado, the company is led by co-founder and CEO Pulak Sharma. Kazmira Pharmacy, launched in January 2026, is described as the first licensed 503A compounding pharmacy in the United States offering pure, THC-free, prescription-only CBD. Cope Now, launched in May 2026 in Colorado, connects patients with licensed clinicians for virtual consultations and prescription fulfillment through the in-house pharmacy, addressing a dosing gap between typical consumer CBD use (under 50 mg/day) and clinically effective therapeutic doses (200-400 mg/day).

The underlying technology centers on pharmaceutical-grade compounding and a vertically integrated telehealth-to-pharmacy workflow rather than a proprietary software or AI stack. The business model generates revenue through telehealth consultation services (described as recurring) and per-prescription sales of pharmacy-compounded CBD. Initial go-to-market is direct-to-consumer via the Cope Now telehealth platform, with an enterprise sales posture toward healthcare provider networks as the company scales into additional states.

The strategic posture is regulatory-tail-driven: Kazmira is positioned as the compliant prescription alternative as federal legislation (H.R. 5371, passed November 2025 with enforcement beginning November 2026) and the December 2025 Executive Order rescheduling cannabis to Schedule III restrict the over-the-counter hemp-derived CBD market. The company has publicly committed to expanding into 20 or more additional states, with Arizona, Florida, Texas, and Utah named as 2026 targets, against a global hemp oil market projected to reach $27.2 billion by 2030.

Name

Kazmira

Legal name

Kazmira LLC

Website

https://kazmira-llc.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Kazmira operates a vertically integrated prescription CBD platform combining the nation's first 503A compounding pharmacy with a direct-to-consumer telehealth service, delivering clinically dosed THC-free CBD to patients who require treatment beyond over-the-counter wellness products.

Ownership category

akta.pro rank

Product category

Compounding Pharmacy and Telehealth Prescription CBD

NAICS

Pharmacies and Drug Retailers (45611), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industries

Compounding & Customized Medication Management Support (HSABALAL), Medical Cannabis Dispensaries (CRANAFAB)

Keywords

• Compounding pharmacy services
• Prescription CBD formulations
• Telehealth cannabis consultations
• Hemp-derived cannabinoid ingredients
• Pharmacy-compounded therapeutics

Headquarters

HQ city

Watkins

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Telehealth Prescription Services: Revenue generated from virtual consultations with licensed clinicians for prescription cannabis and CBD evaluation and treatment plans through the Cope Now platform.
2. Prescription Compounded CBD Products: Sales of pharmacy-compounded, prescription-only CBD products through the vertically integrated Kazmira Pharmacy, serving patients who require clinically effective doses not available through over-the-counter products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

Kazmira operates a vertically integrated prescription cannabinoid platform combining Kazmira Pharmacy, the first licensed 503A compounding pharmacy in the United States offering THC-free, prescription-only CBD, with the Cope Now telehealth platform that delivers virtual consultations with licensed clinicians for personalized CBD treatment plans. The pharmacy compounds pure, THC-free CBD formulations at clinically effective doses of 200-400 mg/day, addressing the dosing gap between typical over-the-counter consumer CBD use (under 50 mg/day) and therapeutic thresholds, with multi-state expansion planned.

Product overview

Kazmira Therapeutics operates a vertically integrated prescription cannabis and CBD product portfolio combining telehealth services with a licensed compounding pharmacy. The core offerings include Kazmira Pharmacy (the nation's first 503A compounding pharmacy offering THC-free, prescription-only CBD) and Cope Now (a telehealth platform for virtual consultations with licensed clinicians to prescribe personalized CBD treatments). These products work together through a vertically integrated model where telehealth evaluations connect patients directly to pharmacy-compounded CBD products, addressing the dosing gap between typical consumer CBD use and clinically effective therapeutic doses.

Differentiator

Problem solved

Functional benefit

Products and services

• Cope Now A telehealth platform providing patients with prescription-only, pharmacy-compounded CBD through virtual consultations with licensed clinicians, delivering clinically effective CBD doses (200-400 mg/day) compared to typical consumer use (under 50 mg/day), launching in Colorado with planned multi-state expansion.
• Kazmira Pharmacy (503A Compounding) First licensed 503A compounding pharmacy in the United States specializing in pure THC-free, prescription-only CBD; LegitScript-certified pharmacy providing evidence-based, clinically prescribed cannabis medicine through a vertically integrated model with the Cope Now telehealth platform.
• Hemp-derived cannabinoid ingredients Science-based manufactured hemp-derived cannabinoid ingredients that serve as the underlying raw inputs for Kazmira Pharmacy's compounded prescription CBD formulations.

Quantifiable outcome

• Addresses dosing requirements of 200-400 mg/day versus typical consumer use of under 50 mg/day

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Tilray Brands: Tilray is a large, publicly traded global cannabis company with operations across cultivation, processing, distribution, and branded medical cannabis products. It is a broad incumbent comparable to Kazmira in the prescription/medical cannabis category but operates across a much wider portfolio and geography.
• Curaleaf Holdings: Curaleaf is a large U.S. multi-state cannabis operator with dispensaries, cultivation, and a growing medical/pharmacy footprint. It is a broad incumbent comparable to Kazmira's medical cannabis dispensary + pharmacy patient services model, though at substantially larger scale and broader product scope.
• Charlotte's Web Holdings: Charlotte's Web is a leading hemp-derived CBD wellness brand selling tinctures, capsules, and topicals through retail and DTC channels. It is a broad incumbent in hemp-derived CBD that Kazmira's prescription model is positioned against as regulations tighten OTC offerings.
• Hims & Hers Health: Hims & Hers is a scaled direct-to-consumer telehealth and prescription platform with national reach across multiple therapeutic categories. It is a broad incumbent comparable to Kazmira's telehealth-plus-prescription model, with substantially greater brand awareness and customer acquisition infrastructure.

Direct peers

• PrestoDoctor: PrestoDoctor provides online medical cannabis evaluations and recommendations via telehealth across multiple U.S. states. It is a direct peer to Kazmira's Cope Now in the cannabis-specific telehealth recommendation space, with comparable multi-state reach ambitions.
• Veriheal: Veriheal is a cannabis telehealth and patient access platform offering virtual consultations with physicians for medical marijuana cards and treatment plans. Like Kazmira's Cope Now, it operates a direct-to-consumer prescription cannabis funnel, making it a direct peer in telehealth-driven cannabis access.
• NuggMD: NuggMD is one of the largest cannabis telehealth platforms in the U.S., connecting patients with licensed physicians for medical cannabis recommendations and prescriptions. It is directly comparable to Kazmira's Cope Now platform on the telehealth + prescription cannabis model, though NuggMD is not vertically integrated with a compounding pharmacy.
• Dutchie: Dutchie is a leading cannabis e-commerce and retail technology platform that has expanded into telehealth and payments infrastructure for dispensaries. It overlaps with Kazmira's telehealth + pharmacy fulfillment model and serves a similar cannabis patient audience.
• Empower Pharmacy: Empower Pharmacy is a large 503A and 503B compounding pharmacy producing customized medications, including hormone and wellness preparations. It is directly comparable to Kazmira Pharmacy on the compounding pharmacy infrastructure side, though it does not currently focus on cannabis-specific formulations.
• Green Health Docs: Green Health Docs is a multi-state cannabis telehealth and certification provider offering online medical marijuana evaluations. It directly mirrors Kazmira's Cope Now in the cannabis telehealth recommendation category and shares the multi-state expansion thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/kazmira_llc
• Facebookfacebook.com/kazmirallc
• LinkedInlinkedin.com/company/kazmira-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kazmira